"fedratinib" meaning in English

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "fedratinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2172:",
          "text": "Fedratinib is a selective JAK2 inhibitor approved for primary and secondary myelofibrosis. An important AE observed with fedratinib is Wernicke’s encephalopathy, which has been observed in patients taking the highest daily dosage (500 mg) (70).",
          "type": "quote"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Janus kinase inhibitors, used for the treatment of myeloproliferative diseases including myelofibrosis."
      ],
      "id": "en-fedratinib-en-noun-K4hYnN1P",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "myeloproliferative",
          "myeloproliferative"
        ],
        [
          "disease",
          "disease"
        ],
        [
          "myelofibrosis",
          "myelofibrosis"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of myeloproliferative diseases including myelofibrosis."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "fedratinib"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "fedratinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2172:",
          "text": "Fedratinib is a selective JAK2 inhibitor approved for primary and secondary myelofibrosis. An important AE observed with fedratinib is Wernicke’s encephalopathy, which has been observed in patients taking the highest daily dosage (500 mg) (70).",
          "type": "quote"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Janus kinase inhibitors, used for the treatment of myeloproliferative diseases including myelofibrosis."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "myeloproliferative",
          "myeloproliferative"
        ],
        [
          "disease",
          "disease"
        ],
        [
          "myelofibrosis",
          "myelofibrosis"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of myeloproliferative diseases including myelofibrosis."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "fedratinib"
}